Vandria

Executive Summary

Vandria is a clinical-stage Swiss biotech company focused on developing first-in-class small molecules that target a novel metabolic pathway to improve mitochondrial function and reduce chronic inflammation. Founded in 2018 and headquartered at the Biopôle campus in Lausanne, the company aims to address a broad range of age-related and chronic diseases, with an initial lead program in CNS disorders. Its proprietary approach targets mitochondrial dysfunction, a key driver of aging and inflammation, offering potential therapeutic applications across multiple therapeutic areas. The company is currently advancing its lead candidate through Phase 1 clinical trials. Vandria's preclinical data suggest its molecule can restore mitochondrial health and dampen inflammatory signals, positioning it as a potential disease-modifying therapy for conditions like neurodegeneration. While still early-stage, the platform's versatility may enable expansion into other age-related indications. Upcoming milestones include initial Phase 1 data readout and potential initiation of Phase 2 studies, which will be critical for validating the mechanism and advancing the pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 clinical data readout for lead CNS program60% success
• H1 2027Announcement of Phase 2 trial initiation50% success
• TBDPartnership or collaboration for non-CNS indication40% success